Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Author's Avatar
Aug 03, 2022

MyMD+Pharmaceuticals%2C+Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today the publication of data in the %3Ci%3EJournal+of+Gerontology%3A+Biological+Sciences%3C%2Fi%3E (JGBS) from a pre-clinical study of MYMD-1® demonstrating four-fold greater improvements than rapamycin in delaying aging and extending the life of mice who began treatment at the human equivalent of 60 years of age. The study was led by principal study investigatorPatrizio P. Caturegli, MD, MPH, a professor of pathology at the Johns Hopkins University School of Medicine.